OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2014 Ann Schreiber Mentored Investigator Award – Yang Yang, PhD

Yang Yang, PhD
Yale University
P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance

Yang Yang

Project Summary
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. EOC patients often develop chemoresistance, which inevitably leads to disease progression. Our research focuses on understanding the mechanism of the resistance to platinum-based treatment in ovarian cancer.

The protein P53 plays a central role in inducing cell death. Therefore, mutation caused inactivation of p53 can lead to chemoresistance. We discovered that even without mutations, in a unique population of ovarian cancer stem cells, wild-type p53 protein can aggregate into an inactive form, due to the deregulation of p53 protein degradation. This inactive form of p53 aggregates is similar to the amyloid fibrils that cause Alzheimer’s and Parkinson’s diseases. Our research will reveal the mechanisms of aggregated p53 protein causing chemoresistance and tumor progression. The proposed study will explain why patients without p53 mutations showed poorer survival and were more resistant to chemotherapies. We will also try to discover small molecules that can inhibit the aggregation of p53 protein as a new therapeutic approach to sensitize chemoresistant cancer cells to conventional therapies and to prevent recurrence and chemoresistance.

Bio
Dr. Yang Yang is a postdoctoral research associate at the Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine. She obtained her bachelor degree in 2003 at the College of Life Science, Nankai University, China and her doctoral degree in 2009 from a joint program supported by Nankai Univerisity and University of Southern California. Her doctoral research fell into two topics: the transcriptional regulation of embryonic stem cells self-renewal and differentiation and the cell-based high-throughput drug discovery. She expanded her research area to the translational research of ovarian cancer and cancer stem cell at Yale School of Medicine. She has authored 16 scientific publications and received the National Award for Outstanding Undergraduate Students in 2003 and the National Study Aboard Award for Ph.D Candidates in 2009.